In a filing, Boston Scientific Corp revealed its EVP & Group Pres, Cardiology Fitzgerald Joseph Michael unloaded Company’s shares for reported $5.27 million on Sep 02 ’25. In the deal valued at $105.43 per share,50,000 shares were sold. As a result of this transaction, Fitzgerald Joseph Michael now holds 178,342 shares worth roughly $17.81 million.
Then, JOSEPH M FITZGERALD bought 50,000 shares, generating $5,271,415 in total proceeds.
Before that, Fitzgerald Joseph Michael sold 50,000 shares. Boston Scientific Corp shares valued at $5,231,670 were divested by the EVP & Group Pres, Cardiology at a price of $104.63 per share. As a result of the transaction, Fitzgerald Joseph Michael now holds 178,342 shares, worth roughly $17.81 million.
Oppenheimer upgraded its Boston Scientific Corp [BSX] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. Needham also remained covering BSX and has increased its forecast on April 16, 2025 with a “Buy” recommendation from previously “Hold” rating. Deutsche Bank revised its rating on January 10, 2025. It rated BSX as “a Buy” which previously was an “a Hold”.
Price Performance Review of BSX
On Monday, Boston Scientific Corp [NYSE:BSX] saw its stock fall -2.77% to $99.87. Over the last five days, the stock has lost -7.65%. Boston Scientific Corp shares have risen nearly 20.41% since the year began. Nevertheless, the stocks have risen 11.81% over the past one year.
How much short interest is there in Boston Scientific Corp?
A steep rise in short interest was recorded in Boston Scientific Corp stocks on 2025-08-29, growing by 2.72 million shares to a total of 18.99 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 16.27 million shares. There was a rise of 14.33%, which implies that there is a positive sentiment for the stock.
